Orris

Gamma delta HSTCL post allo relapse HLH active disease CD38 positive - Dara refractory options

Reading File
Reading File
Reading File
Searching the Web

gamma delta hepatosplenic T cell lymphoma relapse after allogeneic transplant HLH treatment CD38 daratumumab refractory

Searching PubMed

hepatosplenic T-cell lymphoma AND relapse

Searching PubMed

hepatosplenic T-cell lymphoma AND allogeneic transplantation

Searching PubMed

hepatosplenic T-cell lymphoma AND treatment

Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Searching PubMed

"hepatosplenic T-cell lymphoma" AND salvage

Searching PubMed

"hepatosplenic T-cell lymphoma" AND venetoclax

Searching PubMed

"lymphoma-associated hemophagocytic lymphohistiocytosis" AND treatment

Searching the Web

site:clinicaltrials.gov hepatosplenic T cell lymphoma clinical trial gamma delta

Reading Article

PMID: 36980725

Reading Article

PMID: 30383643

Reading Article

PMID: 33856526

Reading Article

PMID: 34409955

Reading Article

PMID: 36349896

Reading Web Page

https://clinicaltrials.gov/study/NCT05475925

Finding Sources
Reading File
Searching PubMed

ruxolitinib AND lymphoma-associated hemophagocytic lymphohistiocytosis

Searching PubMed

"hepatosplenic T-cell lymphoma" AND romidepsin

Searching the Web

DR-01 anti CD94 hepatosplenic T cell lymphoma trial NCT05475925 recruitment

Searching PubMed

"lymphoma-associated hemophagocytic lymphohistiocytosis" AND etoposide

Searching PubMed

"hepatosplenic T-cell lymphoma" AND molecular

Finding Sources
This is an immediately life-threatening scenario. Active lymphoma-associated HLH must be controlled at the same time as the relapsed γδ-HSTCL, not sequentially. Daratumumab-refractory CD38 expression does not by itself identify a validated next targeted treatment for HSTCL.

Practical priority order

1. Stabilize active lymphoma-associated HLH now, while starting lymphoma-directed salvage

  • In adults with malignancy-associated HLH, the usual backbone remains dexamethasone plus etoposide, modified for hepatic and renal dysfunction and marrow reserve. In lymphoma-driven HLH, an etoposide-containing lymphoma regimen is generally preferred because it treats both hyperinflammation and the malignant trigger. Adult malignancy-HLH review and etoposide-focused analysis.
  • Do not wait for ferritin to normalize before treating the lymphoma. Follow clinical trajectory, ferritin, fibrinogen, triglycerides, LFTs, LDH, cytopenias, sIL-2R if available, coagulopathy, and marrow disease.
  • Urgently look for co-triggers in the post-allo setting: EBV, CMV, adenovirus, HHV-6, fungal infection, bacterial sepsis, GVHD and drug toxicity. Infection can coexist with progressive HSTCL and materially changes the safety of immunosuppression.
Ruxolitinib can be considered as an HLH-directed bridge or adjunct when inflammation is not controlled or etoposide is temporarily difficult, but it should not replace prompt lymphoma cytoreduction. Evidence in lymphoma-associated HLH remains limited and includes cautionary reports. A phase II study supports ruxolitinib plus dexamethasone in adult HLH generally, not specifically post-allo HSTCL PMID 40090001.

2. Do not continue daratumumab beyond clear refractoriness

There is no convincing HSTCL-specific evidence that adding bortezomib or venetoclax rescues daratumumab-refractory disease. Venetoclax-based approaches are biologically tempting in T-cell neoplasms but there is no established HSTCL evidence base, and tumor lysis, cytopenia, infection, and interaction concerns are substantial in active HLH after allo-HCT.

Lymphoma-directed options to discuss at an expert center

The evidence here is almost entirely case reports, small series, and extrapolation from relapsed PTCL. There is no standard post-allo salvage for γδ-HSTCL.

A. Cytoreductive, etoposide-containing salvage

For aggressive marrow, liver, spleen, or blood disease with HLH, favor a regimen that includes etoposide and provides fast cytoreduction, selected according to prior exposure and organ function. Options commonly considered include:
  • ICE-like therapy: ifosfamide, carboplatin, etoposide
  • ESHAP-like therapy: etoposide, steroid, cytarabine, platinum
  • High-dose cytarabine/fludarabine-containing therapy, where feasible
  • A disease- and prior-therapy-specific intensive regimen if the patient can tolerate it
In HSTCL, conventional CHOP-like therapy has generally performed poorly; series favor intensive induction followed by allo-HCT when possible. In a 14-patient γδ-HSTCL series, responses followed by allo-HCT were the basis of the durable remissions reported, but data are small and pre-relapse. Clinical series.
Practical caveat: hepatic dysfunction, DIC/hypofibrinogenemia, profound cytopenias, and infection may force a less intensive first step. In that case, HLH-directed dexamethasone/etoposide with a rapid reassessment may be safer than forcing full-dose multi-agent chemotherapy immediately.

B. CD52-directed treatment if the clone is strongly CD52-positive

If flow/IHC confirms uniform CD52 expression, an alemtuzumab-based approach is a biologically reasonable off-label consideration. There is historical HSTCL case-level activity with alemtuzumab plus cladribine reported case.
However, after allo-HCT with active HLH, alemtuzumab carries major risks:
  • severe and prolonged T-cell depletion
  • CMV, EBV, adenovirus, fungal and opportunistic infection
  • delayed immune recovery
  • potentially impaired graft-versus-lymphoma effect
I would regard this as an expert-center option only, with active viral surveillance and antimicrobial planning.

C. PTCL drugs as a bridge, not a proven HSTCL solution

If cytotoxic salvage is unsuitable or fails, treatment may be extrapolated from relapsed PTCL:
  • Romidepsin or belinostat
  • Pralatrexate
  • Azacitidine-based combinations, especially within a clinical trial
  • Possibly a JAK-pathway strategy if molecular profiling provides a rationale
These agents have activity in broader PTCL, but response data in HSTCL, especially post-allo relapse with active HLH, are too sparse to call any one preferred. Marrow reserve and hepatic function are often the limiting factors.

D. Reassess post-allo immune strategy immediately

Obtain:
  • marrow and peripheral blood lineage-specific chimerism
  • current immunosuppression and GVHD status
  • disease distribution and kinetics
  • donor availability and donor-cell product feasibility
Potential interventions:
  1. Careful taper of immunosuppression, if clinically safe and no significant GVHD.
  2. Donor lymphocyte infusion only after disease control is improving and with extreme caution. It may augment graft-versus-lymphoma but can precipitate severe GVHD and intensify inflammatory disease. There is no strong HSTCL-specific DLI dataset.
  3. Second allo-HCT if a remission or deep response can be achieved and performance status/organ function permit. There is at least a documented γδ-HSTCL case of relapse after allo-HCT achieving remission following a second allo-HCT from the same sibling donor, but this is case-report level evidence only. Second-allo case report.

Clinical trial should be pursued urgently

The most directly relevant currently listed study is DR-01 for cytotoxic lymphomas, which explicitly includes HSTCL:
DR-01 is an investigational agent directed at CD94, relevant because HSTCL is a cytotoxic T-cell lymphoma. Trial eligibility must be checked urgently, as uncontrolled HLH, organ dysfunction, active infection, or recent treatment may affect eligibility. Current listings show recruiting US sites.
Another listed relapsed/refractory T-cell lymphoma study includes HSTCL and evaluates belinostat combined with azacitidine or pralatrexate, but this may be unsuitable until HLH and organ dysfunction are controlled:

Minimum workup before choosing the salvage branch

  1. Repeat expert hematopathology: γδ TCR, CD2/3/7, CD4/8, CD5 loss, CD16/56, CD52, CD30, CD38 intensity, PD-1/PD-L1 as locally available.
  2. Molecular panel: specifically assess actionable biology such as STAT5B/JAK-STAT, PI3K-pathway alterations, and SETD2 changes. This mainly supports trial matching rather than routine off-label treatment.
  3. HLH and infection assessment: ferritin trend, fibrinogen, triglycerides, sIL-2R, coagulation, EBV/CMV/adenovirus PCRs, cultures, fungal assessment, imaging.
  4. Transplant review: donor type, chimerism, current GVHD, immunosuppression, prior conditioning and prior toxicity.
  5. Organ-function-adapted regimen selection: bilirubin, AST/ALT, renal clearance, marrow involvement, DIC, and infection status must determine whether intensive salvage is realistic.

Bottom line

For daratumumab-refractory, post-allo γδ-HSTCL with active HLH, the most defensible immediate direction is:
  1. HLH control with dexamethasone plus etoposide-based therapy, adjusted for hepatic/renal dysfunction.
  2. Rapid lymphoma cytoreduction using an etoposide-containing salvage regimen, rather than further CD38 targeting.
  3. Early trial referral, particularly DR-01 if eligibility can be preserved.
  4. If a response is obtained, pursue a post-allo cellular strategy: immunosuppression reduction when safe, highly selective DLI consideration, and assessment for second allo-HCT.
  5. Consider alemtuzumab-based salvage only if CD52 is convincingly positive and infectious risk is manageable.
Confidence is moderate for the HLH-first/lymphoma-directed framework, but low for selection among individual salvage regimens because post-allo relapsed γδ-HSTCL is exceptionally rare and evidence is case-level.
This is a shared conversation. Sign in to Orris to start your own chat.